HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kallis, P. Articles by Treasure, T. Search for Related Content PubMed PubMed Citation Articles by Kallis, P. Articles by Treasure, T.

European Journal of Cardio-Thoracic Surgery, Vol 8, 315-322, Copyright © 1994 by European Association for Cardio-thoracic Surgery

ARTICLES

Aprotinin inhibits fibrinolysis, improves platelet adhesion and reduces blood loss. Results of a double-blind randomized clinical trial

P Kallis, JA Tooze, S Talbot, D Cowans, DH Bevan and T Treasure
Harefield Hospital, Middlesex, UK.

The present recommendation is that aprotinin should be started before cardiac surgery, but as bleeding is only a problem in a minority, most patients are treated unnecessarily. In a prospective, randomised, double-blind trial we have studied the use of aprotinin, given only to the minority of patients who bled significantly post-operatively and who had not received prophylactic aprotinin. Sixty patients, who bled in excess of 400 ml in the first 3 h post-operatively were randomised to receive either aprotinin (2 x 10(6) KIU loading dose followed by an infusion of 0.5 x 10(6) KIU/h for 4 h) or placebo, in addition to conventional treatment. The demographic characteristics and the surgical procedures performed were similar in the two groups. Haematological variables were measured (A) before and (B) at the end of the infusion. Three patients were re-explored for excessive bleeding in each group and one patient died in each group. The patients in the aprotinin group bled significantly less and had higher haemoglobin levels on discharge than the patients in the placebo group. The tissue plasminogen activator antigen decreased and the fibrinogen level increased in the aprotinin group. In addition, aprotinin increased the number of surface GPIb platelet receptors as estimated by flow cytometry (36% versus 5%, P < 0.01) and maintained the platelet von Willebrand Factor activity (vWF). There was no significant difference in D-dimers, fibrin(ogen) degradation products, plasma vWF activity and antigen, platelet vWF antigen, platelet aggregation (to collagen, arachidonic acid, platelet activating factor and ristocetin), platelet count or transfusion of blood products between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. M. Alvarez, L. R. Jackson, C. Chatwin, and J. J. Smolich Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: A prospective, randomized, double-blind, placebo-controlled trial J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 457 - 463. [Abstract] [Full Text] [PDF]

				M. J. Ray, M. M. Hales, L. Brown, M. F. O'Brien, and E. G. Stafford Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit Ann. Thorac. Surg., August 1, 2001; 72(2): 521 - 526. [Abstract] [Full Text] [PDF]

				F. Forestier, S. Belisle, D. Robitaille, R. Martineau, L. P. Perrault, and J.-F. Hardy Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2000; 69(2): 452 - 456. [Abstract] [Full Text] [PDF]

				S. Allen, N. Anastasiou, D. Royston, R. Paniagua, and M. Yacoub EFFECT OF APROTININ ON VASCULAR REACTIVITY OF CORONARY BYPASS GRAFTS J. Thorac. Cardiovasc. Surg., February 1, 1997; 113(2): 319 - 326. [Abstract] [Full Text]

				S. Cicek, U. Demirkilic, E. Ozal, E. Kuralay, H. Bingol, H. Tatar, and O. Y. Ozturk POSTOPERATIVE USE OF APROTININ IN CARDIAC OPERATIONS: AN ALTERNATIVE TO ITS PROPHYLACTIC USE J. Thorac. Cardiovasc. Surg., December 1, 1996; 112(6): 1462 - 1467. [Abstract] [Full Text]

				S. Cicek, U. Demirkilic, E. Kuralay, E. Ozal, and H. Tatar Postoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations Ann. Thorac. Surg., May 1, 1996; 61(5): 1372 - 1376. [Abstract] [Full Text]

				M. J. Unsworth-White, A. Herriot, O. Valencia, J. Poloniecki, E. E. John Smith, A. J. Murday, D. J. Parker, and T. Treasure Resternotomy for Bleeding After Cardiac Operation: A Marker for Increased Morbidity and Mortality Ann. Thorac. Surg., March 1, 1995; 59(3): 664 - 667. [Abstract] [Full Text]